Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 ?l per million cells in 100 ?l staining volume or 5 ?l per 100 ?l of whole blood.

Brilliant Violet 650? excites at 405 nm and emits at 645 nm. The bandpass filter 660/20 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 650? is a trademark of Sirigen Group Ltd.

ELISA or ELISPOT Detection: The biotinylated MAb11 antibody is useful as the detection antibody in a sandwich ELISA or ELISPOT, when used in conjunction with the purified MAb1 antibody (Cat. No. 502802/502804) as the capture antibody.

Flow Cytometry^3,5,6,10: The fluorochrome-labeled MAb11 antibody is useful for intracellular and membrane-bound immunofluorescent staining and flow cytometric analysis to identify TNF-a-producing cells within mixed cell populations.

Additional reported applications (for the relevant formats) include: neutralization^1,2, immunohistochemical staining of paraformaldehyde-fixed, saponin-treated frozen tissue sections⁴ and acetone-fixed frozen tissue sections⁸, immunocytochemistry⁷, and immunofluorescence⁹. The MAb11 antibody can neutralize the bioactivity of natural or recombinant TNF-a.

Note: For testing human TNF-a in serum or plasma, BioLegend's ELISA Max? Sets (Cat. No. 430201 to 430206) are specially developed and recommended. The LEAF? purified antibody (Endotoxin <0.1 EU/?g, Azide-Free, 0.2 ?m filtered) is recommended for neutralization of human TNF-a bioactivity (Cat. No. 502922).

The Purified MAb1 antibody is useful in neutralization² and as the capture antibody in a sandwich ELISA or ELISPOT assay, when used in conjunction with the biotinylated MAb11 antibody (Cat. No. 502904/502914) as the detecting antibody.

Clone MAb11 cross-reacts to Cat¹¹

1. Rathjen D, et al. 1991. Mol. Immunol. 28:79. (Neut)
2. Ablamunits V, et al. 2010. Eur. J. Immunol. 40:2891. (Neut)
3. Enr quez J, et al. 2002. Adv. Perit. Dial. 18:177. (ICFC)
4. Andersson U, et al. 1999. Detection and quantification of gene expression. New York:Springer-Verlag. (IHC)
5. Chen H, et al. 2005. J. Immunol. 175:591. (ICFC)
6. Iwamoto S, et al. 2007. J. Immunol. 179:1449. (ICFC) PubMed
7. Andersson U, et al. 2000. J. Exp. Med. 192:565. (ICC)
8. Moormann AM, et al. 1999. J. Infect. Dis. 180:1987. (IHC)
9. Zhao XJ, et al. 2003. J. Immunol. 170:2923. (IF)
10. Rieger R, et al. 2009. Cancer Gene Ther. 1:53-64. (FC)
11. Maksaereekul S, et al. 2009. Vaccine. 28:3754 (FC)

1. Carre C, et al. 2021. iScience. 24:102970. PubMed
2. Saggau C, et al. 2022. Immunity. :. PubMed
3. Bacher P, et al. 2020. Immunity. . PubMed
4. Sharan R, et al. 2022. J Clin Invest. 132:. PubMed
5. Thompson EA, et al. 2019. Cell Rep. 28:1127. PubMed
6. Sahillioglu AC, et al. 2021. Cancer Immunol Res. 9:999. PubMed
7. Nel I, et al. 2021. Diabetologia. 64(10):2306-2321. PubMed
8. Zhuang X, et al. 2019. Cancer Immunol Res. 0.94375. PubMed
9. Holzer B, et al. 2019. Front Immunol. 2.239583333. PubMed
10. Xu C, et al. 2020. Methods Mol Biol. 2108:159. PubMed
11. Lozano-Ojalvo D, et al. 2021. Cell Rep. 36:109570. PubMed
12. Sekine T, et al. 2020. Cell. 183:158. PubMed
13. K?rner C et al. 2017. Cell host & microbe. 22(1):111-119 . PubMed
14. Wang SQ, et al. 2021. J Viral Hepat. 28:795. PubMed
15. Vierboom MPM, et al. 2021. Cell Reports Medicine. 2(1):100185. PubMed
16. Dijkman K, et al. 2021. Cell Reports Medicine. 2(1):100187. PubMed

1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press, San Diego.
2. Beutler B, et al. 1988. Annu. Rev. Biochem. 57:505.
3. Beutler B, et al. 1989. Annu. Rev. Immunol. 7:625.
4. Tracey K, et al. 1993. Crit. Care Med. 21:S415.